about
p130Cas mediates the transforming properties of the anaplastic lymphoma kinaseRhoA silencing reverts the resistance to doxorubicin in human colon cancer cellsInvolvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growthThe anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL.Molecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells.Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice.The anaplastic lymphoma kinase in the pathogenesis of cancer.The anaplastic lymphoma kinase as an oncogene in solid tumors.Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns.Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cellsModeling lung cancer evolution and preclinical response by orthotopic mouse allografts.Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity.Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1.Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology.NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells.Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.
P50
Q24315788-10FCE948-1E5E-43BA-95DA-923E2D01B6C2Q28297610-3B6D0581-AD42-41C6-9D8F-13CBFE5506EDQ30156817-27782E17-5185-4A13-9570-D376C2D127B7Q30484934-C2DB977B-2CCC-4E30-8FA3-EBA0C42ED603Q34657347-CC9296CF-B396-4B36-9568-C67169877FD8Q35941149-05DFC876-F55B-48AA-BE5A-3693E4004460Q36675069-6DB5597B-1F37-4383-AD1E-3FA3064966FCQ37039605-AF9D40DB-3993-46D8-AE93-D74EA149A1B7Q38472225-A685596E-7F08-4B56-ACEA-3D9C0871E935Q38649517-A9DA410B-E51F-41D9-8508-1C1BDEAFA580Q38716411-E6DD50A5-25BB-438F-B8EE-1546EC1FDA82Q38956964-D0E5ADBD-DBA0-4C67-A131-EDB82AD840FEQ39523446-E3A3FC16-0CF5-4755-B24F-9E1E14433D93Q41561954-962D1035-B96B-48B6-8EE0-E91F2D9A3DE2Q41747565-5E90D987-AB47-4442-90A1-682B1875AB83Q42052786-55AAA5A4-5354-4883-A3BE-28BE179300DEQ42199612-04733AE0-603C-4C15-8731-E0A79A11E31B
P50
description
onderzoeker
@nl
name
Claudia Voena
@ast
Claudia Voena
@en
Claudia Voena
@es
Claudia Voena
@nl
Claudia Voena
@sl
type
label
Claudia Voena
@ast
Claudia Voena
@en
Claudia Voena
@es
Claudia Voena
@nl
Claudia Voena
@sl
prefLabel
Claudia Voena
@ast
Claudia Voena
@en
Claudia Voena
@es
Claudia Voena
@nl
Claudia Voena
@sl
P106
P21
P31
P569
2000-01-01T00:00:00Z